Joint Pro­gram­ming Ini­ti­at­ive on Anti­mi­cro­bi­al Res­ist­ance (JPIAMR) Fund­ing Opportunity

Anti­mi­cro­bi­al res­ist­ance (AMR) affects humans, anim­als and plants equally and knows neither geo­graph­ic­al bound­ar­ies nor spe­cies bar­ri­ers. Pro­gress in com­bat­ing AMR is neces­sary to achieve the United Nations Sus­tain­able Devel­op­ment Goals (SDGs). AMR plays an import­ant role in par­tic­u­lar in the goals of ​“no poverty”, ​“health and well-being”, ​“no hun­ger”, ​“reduced inequal­it­ies” and ​“decent work and eco­nom­ic growth”. The European One Health Action Plan against AMR encour­ages the European Uni­on (EU) and its Mem­ber States to devel­op innov­at­ive, effect­ive and sus­tain­able meas­ures against AMR, in par­tic­u­lar to reduce the occur­rence and spread of AMR with­in and out­side the EU. The grow­ing chal­lenge of AMR requires a hol­ist­ic and multi-sec­tor­al approach in the spir­it of One Health. There­fore, 29 nations are com­mit­ted to the Joint Pro­gram­ming Ini­ti­at­ive on Anti­mi­cro­bi­al Res­ist­ance (JPIAMR) to con­tain AMR with a One Health approach.

State and state-recog­nized uni­ver­sit­ies and non-uni­ver­sity research insti­tu­tions as well as com­mer­cial com­pan­ies are eli­gible to apply. At the time of pay­ment of a grant, the exist­ence of a per­man­ent estab­lish­ment or branch (com­pany) or anoth­er insti­tu­tion that serves the non-eco­nom­ic activ­ity of the grant recip­i­ent (uni­ver­sity, research insti­tu­tion) in Ger­many is required.

The object­ives of the fund­ing meas­ure will be achieved if the res­ults expand know­ledge about the emer­gence and spread of anti­mi­cro­bi­al res­ist­ance or if inter­ven­tions against it are improved or developed. The res­ults of each indi­vidu­al research pro­ject should be pub­lished or pat­en­ted in at least one pub­lic­a­tion in order to con­trib­ute to achiev­ing the object­ives of the fund­ing measure.

Research insti­tu­tions that receive basic fund­ing from the fed­er­al and/​or state gov­ern­ments can only receive pro­ject fund­ing for their addi­tion­al pro­ject-related expenses or costs in addi­tion to their insti­tu­tion­al fund­ing under cer­tain con­di­tions.
For the con­di­tions as to when state aid is/​is not present and to what extent aid-free fund­ing can be provided, see the R&D&I Uni­on framework. 

Small and medi­um-sized enter­prises or ​“SMEs” with­in the mean­ing of this fund­ing guideline are com­pan­ies that meet the require­ments of the EU’s SME defin­i­tion. The applic­ant declares to the grant­ing author­ity his clas­si­fic­a­tion in accord­ance with Annex I GBER as part of the application.